Publications

2024

A Patient With Oral Discomfort and Reduced Oral ApertureChen G, Roy S, Cohen J. A Patient With Oral Discomfort and Reduced Oral Aperture. JAMA 2024, 331: 1147-1148. PMID: 38436993, DOI: 10.1001/jama.2023.25945.
TGFβ1 Drives Integrin Dependent Pericyte Migration and Microvascular Destabilization In Fibrotic DiseasePellowe A, Wu M, Kang T, Chung T, Ledesma-Mendoza A, Herzog E, Levchenko A, Odell I, Varga J, Gonzalez A. TGFβ1 Drives Integrin Dependent Pericyte Migration and Microvascular Destabilization In Fibrotic Disease. American Journal Of Pathology 2024 PMID: 38548268, DOI: 10.1016/j.ajpath.2024.02.021.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 1-12. PMID: 38528257, DOI: 10.1007/s40257-024-00853-4.
Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicityUsmani A, Earland N, Zhang W, Harris P, Bacchiocchi A, Sachs C, Nene A, Chen D, Sznol M, Halaban R, Newman A, Chaudhuri A. Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicity. Cancer Research 2024, 84: 1167-1167. DOI: 10.1158/1538-7445.am2024-1167.
Abstract 4745: A novel combination therapy targeting RAF, MEK and FAK to overcome skin cutaneous melanoma treatment resistanceLubrano S, Faraji F, Cervantes-Villagrana R, Ramirez S, Arang N, Officer A, Rigiracciolo D, Quiroz P, Bacchiocchi A, Halaban R, Coma S, Holmen S, Martini C, Pachter J, Aplin A, Gutkind J. Abstract 4745: A novel combination therapy targeting RAF, MEK and FAK to overcome skin cutaneous melanoma treatment resistance. Cancer Research 2024, 84: 4745-4745. DOI: 10.1158/1538-7445.am2024-4745.
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanomaSu D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.
Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia AreataPiliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini B, Luo X, Woodworth D, Schaefer G, Lejeune A, Wolk R. Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata. SKIN The Journal Of Cutaneous Medicine 2024, 8: s394. DOI: 10.25251/skin.8.supp.394.
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic DiseaseArmillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.
Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment EvolutionHuynh F, Damiani G, Bunick C. Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution. Antibiotics 2024, 13: 268. PMID: 38534703, PMCID: PMC10967558, DOI: 10.3390/antibiotics13030268.
Benzoyl Peroxide Drug Products Form BenzeneKucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Dabestani A, Light D. Benzoyl Peroxide Drug Products Form Benzene. Environmental Health Perspectives 2024, 132: 037702. PMID: 38483533, PMCID: PMC10939128, DOI: 10.1289/ehp13984.
Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research ProgramChen G, Xu S, White M, Cohen J. Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program. British Journal Of Dermatology 2024, ljae103. PMID: 38466772, DOI: 10.1093/bjd/ljae103.
Cosmetic Directors on ACGME Program Requirements: A Cross-Sectional SurveyMinkis K, Stratman E, Shi V, Greywal T, Hu J, Suozzi K, Saikaly S, Ortiz A, Kang B, Alam M, members of the AACD Regulatory E, Kourosh A, Boucher A, Suggs A, Bar A, Cahn B, Robinson C, Schlick C, Hooper D, Antonovich D, Bolotin D, Hoss E, Ghareeb E, Hisham F, Alvarez G, Kuhn H, Luke J, Roberts J, Joo J, Orringer J, Labadie J, Shah K, Ward K, Kelly K, Shahabi L, Kole L, Tolaymat L, Dave L, Council M, Chow M, Yi M, Pearlstein M, Eshaq M, Deng M, Lawrence N, Vashi N, Kibbi N, Schenck O, Elsanadi R, Farah R, Wyles S, Yoo S, Nadir U, Petronic-Rosic V, Levin Y, Nawas Z. Cosmetic Directors on ACGME Program Requirements: A Cross-Sectional Survey. Journal Of The American Academy Of Dermatology 2024 PMID: 38460788, DOI: 10.1016/j.jaad.2024.01.085.
How Efforts to Understand Somatic Mosaicism Will Impact DermatologyMortlock R, Choate K. How Efforts to Understand Somatic Mosaicism Will Impact Dermatology. Journal Of Investigative Dermatology 2024, 144: 453-455. PMID: 38395493, PMCID: PMC11009867, DOI: 10.1016/j.jid.2023.10.007.
Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorumTorres-Piwinski M, Carlson K, Panse G, Girardi M. Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorum. JAAD Case Reports 2024 DOI: 10.1016/j.jdcr.2024.02.029.
Immune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of CasesPach J, Mbonu N, Bhullar S, Cohen J, Leventhal J. Immune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of Cases. Dermatologic Clinics 2024 DOI: 10.1016/j.det.2024.02.012.
Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 583-593. PMID: 38391212, DOI: 10.1111/jdv.19665.
Cutaneous diatoms from diatomaceous earth mimicking myiasis infectionRoy S, Micevic G, McNiff J, Christensen S, Cowper S. Cutaneous diatoms from diatomaceous earth mimicking myiasis infection. Pathology 2024 PMID: 38471986, DOI: 10.1016/j.pathol.2023.12.416.
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the LiteratureBelzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 1-11. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.
533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposureBunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.
504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.
A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring systemNiu N, Roy S, Ko C. A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring system. Journal Of Cutaneous Pathology 2024, 51: 379-386. PMID: 38317537, DOI: 10.1111/cup.14591.
Rapidly progressive subungual gray-brown melanonychiaEcheandia-Francis C, Nock M, Myung P, Zubek A. Rapidly progressive subungual gray-brown melanonychia. JAAD Case Reports 2024, 44: 113-115. PMID: 38414828, PMCID: PMC10897537, DOI: 10.1016/j.jdcr.2024.01.013.
Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndromeHaller C, Leszczynska M, Brichta L, Maier E, Riddington I, Choate K, Levy M. Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome. Pediatric Dermatology 2024 PMID: 38273779, DOI: 10.1111/pde.15523.
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska N, Paul C, Gong Y, Anway S, Tran H, Wolk R, Zwillich S, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal Of Clinical Dermatology 2024, 25: 299-314. PMID: 38263353, PMCID: PMC10867086, DOI: 10.1007/s40257-024-00846-3.
Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in PsoriasisDaniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.
Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed CombinationsGhannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.
Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 AnalysisStein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s357. DOI: 10.25251/skin.8.supp.357.
In‐person validation of the Ichthyosis Scoring SystemEcheandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.
Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed CombinationsGhannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.
Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic DermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.
Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 AnalysisStein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s339. DOI: 10.25251/skin.8.supp.339.
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancyRen J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.
Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitorsBang A, Fay C, LeBoeuf N, Etaee F, Leventhal J, Sibaud V, Arbesman J, Wang J, Kwong B. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research And Treatment 2024, 204: 643-647. PMID: 38224427, DOI: 10.1007/s10549-023-07217-2.
Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trialMesinkovska N, King B, Vañó‐Galván S, Shimomura Y, Jedynak J, McCollam J, Pierce E, Ellinwood A, Sinclair R. Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial. JEADV Clinical Practice 2024 DOI: 10.1002/jvc2.327.
Psoriasis associated with inflammatory bowel disease: a cross‐sectional analysis in the NIH All of Us Research ProgramJoel M, Wride A, Cohen J. Psoriasis associated with inflammatory bowel disease: a cross‐sectional analysis in the NIH All of Us Research Program. International Journal Of Dermatology 2024, 63: e82-e83. PMID: 38204174, PMCID: PMC10922412, DOI: 10.1111/ijd.17015.
Interferon-stimulated neutrophils as a predictor of immunotherapy responseBenguigui M, Cooper T, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr S, Shaked Y. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 2024, 42: 253-265.e12. PMID: 38181798, PMCID: PMC10864002, DOI: 10.1016/j.ccell.2023.12.005.
Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature ReviewTurner N, Ko C, McNiff J, Galan A. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review. American Journal Of Dermatopathology 2024, 46: 21-30. PMID: 37982498, DOI: 10.1097/dad.0000000000002584.

2023

Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology servicePach J, Nelson C, Leventhal J. Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service. JAAD International 2023, 15: 21-23. PMID: 38371669, PMCID: PMC10869938, DOI: 10.1016/j.jdin.2023.11.011.
Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetXGarate D, Thang C, Damsky W, Rosenbach M, Golovko G, Wilkerson M, Barbieri J. Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetX. Journal Of The American Academy Of Dermatology 2023, 90: 862-864. PMID: 38147901, DOI: 10.1016/j.jaad.2023.12.028.
Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine stainingHwang E, Lee T, Okifo K, Murphy M, Damsky W. Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine staining. International Journal Of Dermatology 2023 PMID: 38135676, DOI: 10.1111/ijd.16998.
Depression in patients with Raynaud’s phenomenon: A case-control study in the National Institutes of Health's A ll of Us Research ProgramChen G, Shaw K, Xu S, Hashemi K, Castillo R, Vleugels R, Cohen J. Depression in patients with Raynaud’s phenomenon: A case-control study in the National Institutes of Health's A ll of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 857-859. PMID: 38128831, DOI: 10.1016/j.jaad.2023.12.015.
Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in miceTran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.
Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research programChen G, Fan R, Leasure A, Levey D, Damsky W, Cohen J. Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research program. Archives Of Dermatological Research 2023, 316: 11. PMID: 38038754, DOI: 10.1007/s00403-023-02767-3.
Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévèreQuiles-Tsimaratos N, da Rosa J, Simpson E, Soong W, Antaya R, Imafuku S, Pilger S, Litman T, Røpke M, Arlert P, Guttman-Yassky E. Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévère. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a61. DOI: 10.1016/j.fander.2023.09.042.
Analyse de la tolérance du baricitinib chez les patients adultes atteints de pelade sévère issus de 2 essais cliniques randomisés sur une période d’exposition médiane de 1,6 années et maximale de 3,6 annéesKing B, Ko J, Piraccini B, Shimomura Y, Dutronc Y, Wu W, Yang F, Holzwarth K, Chiasserini C, Sinclair R, Leveque C. Analyse de la tolérance du baricitinib chez les patients adultes atteints de pelade sévère issus de 2 essais cliniques randomisés sur une période d’exposition médiane de 1,6 années et maximale de 3,6 années. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a348-a349. DOI: 10.1016/j.fander.2023.09.595.
Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Guanglei Y, Chiasserini C, Somani N, King B, Leveque C. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a336-a337. DOI: 10.1016/j.fander.2023.09.580.
Analyse intégrée de la tolérance de ritlécitinib dans le traitement de la pelade, données issues des phases 2 et phases 3 du programme de développement clinique ALLEGROKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Rodney S, Anway S, Wajsbrot D, Lejeune A, Zwillich S. Analyse intégrée de la tolérance de ritlécitinib dans le traitement de la pelade, données issues des phases 2 et phases 3 du programme de développement clinique ALLEGRO. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a364-a365. DOI: 10.1016/j.fander.2023.09.614.
Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in miceJackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.
Obstructive sleep apnea among patients with psoriasis: A case-control study in the All of Us Research ProgramShaw V, Tobias L, Cohen J. Obstructive sleep apnea among patients with psoriasis: A case-control study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 666-668. PMID: 38008412, DOI: 10.1016/j.jaad.2023.11.031.
Association between atopic dermatitis and hypertension and hyperlipidemia: A cross-sectional study in the All of Us Research ProgramCraver A, Chen G, Cohen J. Association between atopic dermatitis and hypertension and hyperlipidemia: A cross-sectional study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 819-821. PMID: 38008413, DOI: 10.1016/j.jaad.2023.11.026.
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia AreataSenna M, Kwon O, Piraccini B, Sinclair R, Ball S, Ding Y, Chen Y, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatology And Therapy 2023, 13: 3209-3220. PMID: 37991697, PMCID: PMC10689319, DOI: 10.1007/s13555-023-01063-2.
Association between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research ProgramJoel M, Damsky W, Cohen J, Wride M. Association between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research Program. Clinical And Experimental Dermatology 2023, 49: 390-392. PMID: 37967342, PMCID: PMC10957220, DOI: 10.1093/ced/llad397.
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.
Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 StudyPiliang M, Lynde C, King B, Mirmirani P, Sinclair R, Wolk R, Zwillich S, Tran H, Zhang F, Takiya L. Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study. SKIN The Journal Of Cutaneous Medicine 2023, 7: s293. DOI: 10.25251/skin.7.supp.293.
Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Kolodsick J, Yu G, Liu C, Chiasserini C, Piraccini B. Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2. SKIN The Journal Of Cutaneous Medicine 2023, 7: s296. DOI: 10.25251/skin.7.supp.296.
Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic DermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichnfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2023, 7: s251. DOI: 10.25251/skin.7.supp.251.
Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial ProgramKing B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Anway S, Wajsbrot D, Lejeune A, Zwillich S. Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. SKIN The Journal Of Cutaneous Medicine 2023, 7: s291. DOI: 10.25251/skin.7.supp.291.
Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT StudiesSoung J, King B, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Wajsbrot D, Tran H, Wolk R. Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies. SKIN The Journal Of Cutaneous Medicine 2023, 7: s294. DOI: 10.25251/skin.7.supp.294.
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authorsShipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.
Inhibition of T-cell activity in alopecia areata: recent developments and new directionsPasseron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin D, Randhawa S, Winkler A, Telliez J, Martin D, Lejeune A. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers In Immunology 2023, 14: 1243556. PMID: 38022501, PMCID: PMC10657858, DOI: 10.3389/fimmu.2023.1243556.
1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanomaMicevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma. 2023, a1133-a1133. DOI: 10.1136/jitc-2023-sitc2023.1025.
Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human SkinBolsoni J, Liu D, Mohabatpour F, Ebner R, Sadhnani G, Tafech B, Leung J, Shanta S, An K, Morin T, Chen Y, Arguello A, Choate K, Jan E, Ross C, Brambilla D, Witzigmann D, Kulkarni J, Cullis P, Hedtrich S. Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin. ACS Nano 2023, 17: 22046-22059. PMID: 37918441, PMCID: PMC10655174, DOI: 10.1021/acsnano.3c08644.
1437 Proteomic profiling of tumor microenvironment in desmoplastic melanoma using the nanostring geomx digital spatial profilerSu D, Schoenfeld D, Ibrahim W, Baumann R, Rimm D, Kluger H, Olino K, Galan A, Clune J. 1437 Proteomic profiling of tumor microenvironment in desmoplastic melanoma using the nanostring geomx digital spatial profiler. 2023, a1600-a1600. DOI: 10.1136/jitc-2023-sitc2023.1437.
207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architectureGarritano J, Kidacki M, Cho C, Lopez-Giraldez F, Damsky W, Chen L, Vesely M. 207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture. Journal Of Investigative Dermatology 2023, 143: s367. DOI: 10.1016/j.jid.2023.09.215.
67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studiesKing B, Mirmirani P, Sicco K, Ramot Y, Sinclair R, Asfour L, Ezzedine K, Paul C, Edwards R, Kerkmann U, Wajsbrot D, Zwillich S, Lejeune A. 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies. Journal Of Investigative Dermatology 2023, 143: s344. DOI: 10.1016/j.jid.2023.09.075.
Associations between ichthyosis and mood disorders: A case-control study in the All of Us Research ProgramChen G, Goldust M, Choate K, Cohen J. Associations between ichthyosis and mood disorders: A case-control study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 439-440. PMID: 37863200, DOI: 10.1016/j.jaad.2023.10.025.
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
Bulk and single-nucleus RNA sequencing highlight immune pathways induced in individuals during an Ixodes scapularis tick biteTang X, Lynn G, Cui Y, Cerny J, Arora G, Tomayko M, Craft J, Fikrig E. Bulk and single-nucleus RNA sequencing highlight immune pathways induced in individuals during an Ixodes scapularis tick bite. Infection And Immunity 2023, 91: e00282-23. PMID: 37846980, PMCID: PMC10652856, DOI: 10.1128/iai.00282-23.
Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitisMurphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.
Treatment options for necrobiosis lipoidica: a systematic reviewNihal A, Caplan A, Rosenbach M, Damsky W, Mangold A, Shields B. Treatment options for necrobiosis lipoidica: a systematic review. International Journal Of Dermatology 2023, 62: 1529-1537. PMID: 37772666, DOI: 10.1111/ijd.16856.
IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell LymphomaWong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.
Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016Chang J, Nock M, Cohen J, Bunick C. Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016. PLOS ONE 2023, 18: e0290763. PMID: 37733776, PMCID: PMC10513303, DOI: 10.1371/journal.pone.0290763.
Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5Chen Y, Su H, Zhao J, Na Z, Jiang K, Bacchiocchi A, Loh K, Halaban R, Wang Z, Cao X, Slavoff S. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5. Cell Reports 2023, 42: 113145. PMID: 37725512, PMCID: PMC10629662, DOI: 10.1016/j.celrep.2023.113145.
Association of psoriasis and systemic lupus erythematosus and mediation effects of tumor necrosis factor-α inhibitors: A cross-sectional study in the All of Us Research ProgramChen G, Hong S, Ramachandran S, Gehlhausen J, Cohen J. Association of psoriasis and systemic lupus erythematosus and mediation effects of tumor necrosis factor-α inhibitors: A cross-sectional study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 90: 184-187. PMID: 37734665, DOI: 10.1016/j.jaad.2023.09.028.
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsNoelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.
Antimicrobial Wound Dressings: A Concise Review for CliniciansYousefian F, Hesari R, Jensen T, Obagi S, Rgeai A, Damiani G, Bunick C, Grada A. Antimicrobial Wound Dressings: A Concise Review for Clinicians. Antibiotics 2023, 12: 1434. PMID: 37760730, PMCID: PMC10526066, DOI: 10.3390/antibiotics12091434.
IL-6 trans-signaling in a humanized mouse model of sclerodermaOdell I, Agrawal K, Sefik E, Odell A, Caves E, Kirkiles-Smith N, Horsley V, Hinchcliff M, Pober J, Kluger Y, Flavell R. IL-6 trans-signaling in a humanized mouse model of scleroderma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306965120. PMID: 37669366, PMCID: PMC10500188, DOI: 10.1073/pnas.2306965120.
43437 Ustekinumab for the Treatment of Metastatic Crohn DiseaseMcKay G, Coromilas A, Liu L, Murphy M, Punyamurthy N, Damsky W, Wanat K, Rosenbach M, Caplan A, LaSenna C, Shields B. 43437 Ustekinumab for the Treatment of Metastatic Crohn Disease. Journal Of The American Academy Of Dermatology 2023, 89: ab103. DOI: 10.1016/j.jaad.2023.07.414.
44140 Obsessive-Compulsive Disorder Among Patients with Atopic Dermatitis: A Case-Control Study in the All of Us Research ProgramChen G, Fan R, Leasure A, Damsky W, Cohen J. 44140 Obsessive-Compulsive Disorder Among Patients with Atopic Dermatitis: A Case-Control Study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 89: ab69. DOI: 10.1016/j.jaad.2023.07.279.
44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevusMirza F, Yumeen S, Mirza H, Zogg C, Leventhal J, Cohen J. 44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevus. Journal Of The American Academy Of Dermatology 2023, 89: ab208. DOI: 10.1016/j.jaad.2023.07.835.
43852 JAK inhibitor safety compared to traditional systemic immunosuppressive therapiesBunick C, Daniele S. 43852 JAK inhibitor safety compared to traditional systemic immunosuppressive therapies. Journal Of The American Academy Of Dermatology 2023, 89: ab60. DOI: 10.1016/j.jaad.2023.07.242.
43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed CombinationsGhannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Gold L, Kircik L, Harper J. 43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. Journal Of The American Academy Of Dermatology 2023, 89: ab20. DOI: 10.1016/j.jaad.2023.07.089.
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.
Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic.Borash J, Bunick C, Graber E. Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic. Journal Of Drugs In Dermatology 2023, 22: 1061. PMID: 37801533, DOI: 10.36849/jdd.7138.
Successful treatment of facial telangiectasia from carcinoid syndrome with pulsed dye laser therapyJiang R, Leventhal J, Suozzi K. Successful treatment of facial telangiectasia from carcinoid syndrome with pulsed dye laser therapy. JAAD Case Reports 2023, 40: 103-105. PMID: 37771359, PMCID: PMC10523418, DOI: 10.1016/j.jdcr.2023.08.022.
Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomesHashemi D, Nelson C, Nyberg M, Das M, Rosenbach M. Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomes. Journal Of The American Academy Of Dermatology 2023, 89: 1305-1306. PMID: 37633461, DOI: 10.1016/j.jaad.2023.08.048.
Persistent oral ulcers in a woman with thymomaLockwood N, Bhullar S, Panse G, Leventhal J. Persistent oral ulcers in a woman with thymoma. JAAD Case Reports 2023, 41: 40-43. PMID: 37842161, PMCID: PMC10568229, DOI: 10.1016/j.jdcr.2023.08.015.
HIF-1 regulates pathogenic cytotoxic T cells in lupus skin diseaseLittle A, Chen P, Vesely M, Khan R, Fiedler J, Garritano J, Islam F, McNiff J, Craft J. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 2023, 8: e166076. PMID: 37526979, PMCID: PMC10543720, DOI: 10.1172/jci.insight.166076.
Lichen Nitidus: A Case of Tiny, Shiny, Skin BumpsKimball K, Damsky W, Richmond J. Lichen Nitidus: A Case of Tiny, Shiny, Skin Bumps. Frontiers For Young Minds 2023, 11: 1033760. DOI: 10.3389/frym.2023.1033760.
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccinationAsashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.
Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical StudyDamiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri S, Bianchi V, Grada A, Garbarino S, Bunick C. Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study. Dermatology And Therapy 2023, 13: 2229-2246. PMID: 37573289, PMCID: PMC10539244, DOI: 10.1007/s13555-023-00987-z.
PRAME‐negativity in sclerosing nevi with pseudomelanomatous features supports classification as an indolent lesionTang H, McNiff J, Glusac E, Ko C. PRAME‐negativity in sclerosing nevi with pseudomelanomatous features supports classification as an indolent lesion. Journal Of Cutaneous Pathology 2023, 50: 1001-1005. PMID: 37565491, DOI: 10.1111/cup.14505.
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease PathogenesisHwang E, Abdelghaffar M, Shields B, Damsky W. Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis. JID Innovations 2023, 3: 100220. PMID: 37719661, PMCID: PMC10500476, DOI: 10.1016/j.xjidi.2023.100220.
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor OutcomesVesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and managementWei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosisWei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.
Association of atopic dermatitis with schizophrenia and schizoaffective disorderFan R, Chen G, Leasure A, Johnson M, Damsky W, Cohen J. Association of atopic dermatitis with schizophrenia and schizoaffective disorder. Archives Of Dermatological Research 2023, 315: 2731-2733. PMID: 37495709, DOI: 10.1007/s00403-023-02674-7.
Association between uveitis and Lichen planus in the all of us research programMurphy M, Heyang M, Fan R, Leasure A, Damsky W, Cohen J. Association between uveitis and Lichen planus in the all of us research program. Archives Of Dermatological Research 2023, 315: 2729-2730. PMID: 37488318, DOI: 10.1007/s00403-023-02675-6.
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.
IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memoryMicevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.

Download Full List